Publix recalls baby food pouches after testing finds elevated levels of lead
The supermarket chain Publix has recalled fruit and vegetable baby food sold in eight states because product testing found elevated levels of lead, according to federal health officials.
Publix recalled 4-ounce Greenwise Pear, Kiwi, Spinach & Pea Baby Food pouches sold at more than 1,400 stores.
The pouches were produced by Bowman Andros, a French company with a manufacturing plant in Mount Jackson, Virginia, according to the company's website. Publix issued the voluntary recall on May 9, but it wasn't added to the U.S. Food and Drug Administration recall list until late Thursday.
The potential contamination was flagged by officials in North Carolina, the state that first identified a 2023 lead poisoning outbreak linked to tainted applesauce pouches that sickened more than 500 U.S. children.
Routine sampling of the baby food pouches found lead levels at 13.4 parts per billion, according to North Carolina agriculture officials. That exceeds the FDA's recommended limit of 10 parts per billion for such products intended for babies and young children.
Publix said all the potentially contaminated products have been removed from store shelves. No illnesses have been reported, the company said. Customers can return the pouches to local stores for full refund.
This is the second baby food pouch recall because of potential lead contamination in two months. In March, Target recalled more than 25,000 packages of its store brand Good & Gather Baby Pea, Zucchini, Kale & Thyme Vegetable Puree because of elevated lead levels.
North Carolina collaborates with the FDA to conduct routine testing of food products, officials said.
In 2023, state health officials investigated reports of lead poisoning in four children who consumed WanaBana apple cinnamon fruit puree. Those findings led to the detection of a nationwide outbreak linked to the pouches, which were widely sold in Dollar Tree and other stores. Tests showed they contained lead at levels 2,000 times higher than the FDA's maximum recommended level, as well as chromium.
Federal health officials eventually identified 566 cases of confirmed, probable or suspected cases of lead poisoning tied to the pouches in 44 states.
The U.S. Centers for Disease Control and Prevention's childhood lead poisoning program investigated the applesauce outbreak and coordinated state and federal response. However, the program was eliminated in April as part of federal funding cuts under the Trump administration.
CDC officials didn't say whether or how the agency would respond to a similar outbreak now. A spokesperson said the agency is aware of the Publix baby food recall but hasn't been asked to assist with any investigation.
There is no safe level of lead exposure, according to CDC. While the heavy metal is toxic to people of all ages, it can be especially harmful to children, causing damage to the brain and nervous system and slow growth and development.
Heavy metals like lead can get into food products from soil, air, water or industrial processes, according to the American Academy of Pediatrics.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
an hour ago
- The Hill
How thousands of unreviewed ingredients got into our food — and what FDA can do about it
At least 1,000 ingredients in food products on our grocery store shelves have never been checked for safety by the Food and Drug Administration. Dozens have raised serious safety concerns among experts. How did the FDA allow this? The answer can be found in the agency's lax interpretation of a little-known legal designation that lets companies decide for themselves if ingredients in their products are safe. Fortunately, there are steps the agency can take right now to stem the flow of potentially unsafe ingredients into our food supply. Environmental Defense Fund outlined these steps in a letter we recently sent to the agency, but first let's take a closer look at how we got here. 'Generally Recognized as Safe' is a designation Congress created in 1958 to allow commonly used food ingredients to bypass the FDA's pre-market safety review process. It was meant for food substances — such as oils, vinegar, baking soda and common spices — that were widely considered safe due to their long history of everyday use. Since 1958, this status has been coopted to cover a universe of foods that extends far beyond its original intent. According to FDA regulations, a chemical can receive the designation if experts widely agree that scientific evidence shows its use to be safe. But because 'Generally Recognized as Safe' wasn't meant for newer ingredients, Congress allowed ingredients so designated to skip the FDA's premarket approval process — despite requiring similar evidence for other additives. Under the agency's current interpretation, companies can designate the use of a substance as safe and take products with that substance to market without informing the FDA or the public of its decision. While companies may voluntarily submit a notice to FDA offering safety evidence, they are not required to — and often don't. Our organization estimated that manufacturers have notified FDA of fewer than half of the ingredients they market as safe under the 'Generally Recognized' standard. Companies that do bother to submit a notice to the FDA are free to withdraw it at any point and take their product to market, provided they can cite evidence of its safe use. But this 'evidence' is often far from independent. Companies can, and often do, enlist their own employees or handpicked consultants to conduct their safety assessments. The result is a process riddled with conflicts of interest that lets unsafe foods into Americans' homes. We analyzed 'Generally Recognized as Safe' notices received by the FDA, obtained via a Freedom of Information request, and found that of the 1,163 submitted by companies between 1997 and April 2024, 192 were later withdrawn, with safety concerns cited in at least a dozen cases. We also identified 31 ingredients that companies have advertised to be recognized as safe, such as in press releases, trade publications and on their own websites (see the Appendix of our letter). However, we were unable to find the scientific evidence required under this standard to demonstrate these ingredients are commonly regarded as safe among experts. This raises red flags that FDA should be taking seriously. Although a comprehensive fix to the 'Generally Recognized' standard will require legislation from Congress, there are significant steps the FDA can take right away to ensure a more rigorous determination process that better protects Americans' health. Starting today, the FDA can use existing authority to remove safe designations from ingredients it deems unsafe and take them off the market. It can also notify manufacturers, importers, distributors and retailers that the substance is no longer recognized as safe. In addition, the FDA can enforce the requirement that companies base safety designations on publicly available data. Although this won't curtail companies' ability to self-declare substances as safe, it will require those who do to be transparent in citing their evidence. Third, the FDA can enforce the requirement that safety assessments consider vital health information such as a substance's dietary sources, potential cancer risks and the cumulative health effects of similar substances. Finally, the FDA can make companies revise and resubmit their data for review when they submit 'Generally Recognized as Safe' notices that fail to comply with the criteria. The 'Generally Recognized as Safe' designation is far from a perfect system, but it can work better if it is interpreted and enforced more comprehensively. If the FDA is serious about protecting public health, it should start by fully exercising the tools already at its disposal. Maria Doa is senior director at the Chemicals Policy at Environmental Defense Fund. Maricel Maffini is an independent consultant focused on human and environmental health and chemical safety.
Yahoo
an hour ago
- Yahoo
Federal cuts force families to make difficult, and potentially deadly, choices
A mother rushes into the emergency department cradling her 6-month-old baby. He is lethargic, seizing and in critical condition. The cause? Severely low sodium levels in his blood — a result of formula diluted with extra water to make it last longer. With grocery prices climbing and her SNAP benefits running out before the end of the month, she felt she had no other choice. This story is not an outlier. Pediatric clinicians across Wisconsin are seeing the real and devastating consequences of policies that fail to prioritize the health and well-being of children and families. And now, the situation could get worse. The Trump Administration's proposed 'skinny' budget for Fiscal Year 2026 includes deep and dangerous cuts to federal programs that form the backbone of public health in our communities. These proposed reductions include: $18 billion from the National Institutes of Health – stalling critical pediatric research and innovation $3.5 billion from the Centers for Disease Control and Prevention – compromising disease surveillance, immunization programs, and emergency response efforts $1.73 billion from the Health Resources and Services Administration – cutting access to essential primary and preventive care services for children and families $674 million from the Centers for Medicare & Medicaid Services – threatening the Medicaid and CHIP programs that provide health coverage to nearly half of Wisconsin's children. Opinion: We asked readers about wake boats on Wisconsin lakes. Here's what you said. And as if that weren't enough, further reductions to SNAP and other nutrition support programs are also on the table. These aren't just numbers on a spreadsheet. These are lifelines. Vital services that help children survive and thrive. When families can't afford formula, when clinics lose funding for immunization programs, when children lose health coverage, the consequences are immediate and, in many cases, irreversible. As front-line providers, we witness this every day. We can do better. Our federal budget is a reflection of our national values. It should not balance its books on the backs of our youngest and most vulnerable. I implore Wisconsin's elected officials to reject this harmful budget proposal. Think of that infant in the emergency room. Think of the thousands of other children across our state whose health and future depend on robust public health infrastructure, access to care, and support for families in need. We urge lawmakers to work toward a bipartisan budget that invests in children, strengthens public health, and protects the building blocks of a healthy society. Wisconsin's children deserve every opportunity to grow up healthy and strong. Our chapter of the National Association of Pediatric Nurse Practitioners stands ready to partner in this effort. Let's move forward — not backward — when it comes to the health of our children. Christine Schindler is a critical care pediatric nurse practitioner at Children's WI, a clinical professor at Marquette University, and the President of the Wisconsin Chapter of Pediatric Nurse Practitioners. She has been caring for critically ill and injured children for almost 30 years. All opinions expressed are her own. This article originally appeared on Milwaukee Journal Sentinel: Trump budget jeopardizes health of American children | Opinion
Yahoo
an hour ago
- Yahoo
Psychedelics as potential mental health treatment are explored by Trump administration
The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared. "The Department shares the goal of ensuring that all Americans — especially our nation's veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression," a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. "Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges." Fda Approves First Ai Tool To Predict Breast Cancer Risk In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin ("magic mushrooms") to treat mental health disorders. MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings. Read On The Fox News App Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has "a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision." Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico. Psychedelic medicines are "showing real promise," according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London. Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves. Common Supplements And Medications Could Cause Liver Damage, Studies Show "Take psilocybin, for example — it's demonstrating remarkable results for severe depression that hasn't responded to other medications," he told Fox News Digital. "MDMA is showing similar breakthroughs for PTSD treatment." Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added. Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. "Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it's crucial that we complete this research properly," he said. "The goal is to bring safe, proven psychedelic therapies to the patients who need them most." At President Trump's May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that "we're opening up the possibility of psychedelic treatment." Retired Army Sergeant Jonathan Lubecki recently told Fox News' Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. "[I] took my first dose of MDMA. I've only taken it three times as part of the clinical trial, haven't taken it since, and haven't found the need to take it since, because I haven't had PTSD," he said. Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. Fallujah Vet Turns Medal Of Heroism Into A Healing Mission For Fellow Warriors With Service Dogs Program "Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions," he said. The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate. "The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions," said Kasperowicz. An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is "unlike classical psychedelics." The study noted, "MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs." Click Here To Sign Up For Our Health Newsletter The researchers concluded that MDMA showed "enhanced levels of trust, empathy, self-compassion and a 'window of tolerance'" that traditional psychotherapy lacks. Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that "the time is now to address the mental health crisis." He said it is "gratifying" that administration officials value the potential benefits of looking into alternative mental health treatments. Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD). "In Cybin's completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003," said Drysdale. Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News' senior medical analyst, previously interviewed two of the country's top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone. "They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses," Siegel told Fox News Digital at the time. "Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts," Siegel added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it's important to administer psychedelics in a safe setting when treating mental health conditions. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed article source: Psychedelics as potential mental health treatment are explored by Trump administration
